Gabriel Eckenstein

OUR PURPOSE Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic technologies. OUR CREDENTIALS Kuros is a Swiss-headquartered biotech company, listed on the SIX Swiss Stock Exchange since 2016 (under symbol KURN). With additional operations in the Netherlands and the USA, we continue to grow our global team. To deliver the ideal bone graft, you need the highest quality and quantity of scientific evidence behind it. We believe that this is a key differentiator for Kuros, given the urgent need to advance bone healing. • Listing on the 𝗦𝗜𝗫 𝗦𝘄𝗶𝘀𝘀 𝗘𝘅𝗰𝗵𝗮𝗻𝗴𝗲 under the symbol KURN since 2016 • A commercial & research footprint that spans >𝟮𝟬 𝗺𝗮𝗿𝗸𝗲𝘁𝘀 • Dozens of 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗮𝗻𝗱 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗲𝘅𝗽𝗲𝗿𝘁 𝗮𝗱𝘃𝗶𝘀𝗲𝗿𝘀 • >𝟮𝟱 orthobiologics-related 𝗽𝗮𝘁𝗲𝗻𝘁𝘀 • >𝟰𝟬𝟬 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗲𝘃𝗮𝗹𝘂𝗮𝘁𝗲𝗱 in Level I, randomized controlled clinical trials • >𝟮𝟬 well-controlled 𝗟𝗲𝘃𝗲𝗹 𝗜-𝗜𝗩 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 𝗶𝗻𝗶𝘁𝗶𝗮𝘁𝗲𝗱, including 6 that are complete¹ • Published Level I evidence published in 𝑆𝑝𝑖𝑛𝑒 CONTACT KUROS TO FIND OUT MORE >>>>

Leading Technology for the Encapsulation of nucleic acids, biomolecules, and other APIs. Our technology solves your current encapsulation challenges. We offer highly flexible GMP manufacturing solutions for your genetic payloads and other molecules, making manufacturing of transfection material a highly flexible and commercially viable proposition. LEON utilises its’ proprietary nano technology platform for the continuous manufacturing of SMART nanoparticles (ranging from surface stablilised polymeric through to lipid nanoparticles (LNPs) and liposomes). The Company is working with world class industry partners for both process and product development.

OUR PURPOSE Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic technologies. OUR CREDENTIALS Kuros is a Swiss-headquartered biotech company, listed on the SIX Swiss Stock Exchange since 2016 (under symbol KURN). With additional operations in the Netherlands and the USA, we continue to grow our global team. To deliver the ideal bone graft, you need the highest quality and quantity of scientific evidence behind it. We believe that this is a key differentiator for Kuros, given the urgent need to advance bone healing. • Listing on the 𝗦𝗜𝗫 𝗦𝘄𝗶𝘀𝘀 𝗘𝘅𝗰𝗵𝗮𝗻𝗴𝗲 under the symbol KURN since 2016 • A commercial & research footprint that spans >𝟮𝟬 𝗺𝗮𝗿𝗸𝗲𝘁𝘀 • Dozens of 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗮𝗻𝗱 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗲𝘅𝗽𝗲𝗿𝘁 𝗮𝗱𝘃𝗶𝘀𝗲𝗿𝘀 • >𝟮𝟱 orthobiologics-related 𝗽𝗮𝘁𝗲𝗻𝘁𝘀 • >𝟰𝟬𝟬 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗲𝘃𝗮𝗹𝘂𝗮𝘁𝗲𝗱 in Level I, randomized controlled clinical trials • >𝟮𝟬 well-controlled 𝗟𝗲𝘃𝗲𝗹 𝗜-𝗜𝗩 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 𝗶𝗻𝗶𝘁𝗶𝗮𝘁𝗲𝗱, including 6 that are complete¹ • Published Level I evidence published in 𝑆𝑝𝑖𝑛𝑒 CONTACT KUROS TO FIND OUT MORE >>>>

Leading Technology for the Encapsulation of nucleic acids, biomolecules, and other APIs. Our technology solves your current encapsulation challenges. We offer highly flexible GMP manufacturing solutions for your genetic payloads and other molecules, making manufacturing of transfection material a highly flexible and commercially viable proposition. LEON utilises its’ proprietary nano technology platform for the continuous manufacturing of SMART nanoparticles (ranging from surface stablilised polymeric through to lipid nanoparticles (LNPs) and liposomes). The Company is working with world class industry partners for both process and product development.

Beyond Capital Fund is an evergreen impact investment fund that invests in for-profit, early-stage companies throughout East Africa and India. The fund invests in businesses that are focused on greater access to health care, sanitation, clean energy, agriculture & food security, and financial inclusion, which can increase the quality of life for consumers living at the bottom of the economic pyramid. Though the fund seeks market-rate financial returns, Beyond Capital is structured as a nonprofit, which permits the organization to emphasize fidelity to its social mission alongside its financial mandate. Since its founding in 2009, Beyond Capital has reached a growing 8 million people, including 5.8 million women, living in underserved communities.

Leukocare AG, located in Martinsried/Munich, Germany and Milford, MA, USA, is the leading innovator for drug product development of biologics for many modalities with services specializing in drug product development tailored to the target product profile. Leukocare provides superior stabilization and optimal formulation of the drug product to increase shelf life and improve logistics, reducing risks in drug development programs. Leukocare is different from other companies in that bioinformatics and biostatistics-based approaches are used in the Design of Experiment (DoE) to explore a broader design space than conventional methods in order to find the best combination of excipients. This is achieved by synergizing in-silico methods with wet lab experiments, which reduces the number of experiments needed or the need for high throughput, resulting in the use of less drug substance and reduced development time. Our strength is that we draw on our database of over 100+ regulatory approved excipients, reducing the hurdles later in the clinic. In addition to formulation development services, Leukocare offers analytical and bioinformatics services for already in-process drug discovery and development projects. Our robust analytical expertise is applied to services ranging from particle characterization, stability and molecular integrity analysis, and long-term stability prediction to non-GMP filling for toxicology studies or molecular modeling and to help in candidate selection of drug substances.

Since 1999 Thomas Bachmann and Gabriel Eckenstein have been dealing and consulting in Japanese art. Thomas Bachmann and Gabriel Eckenstein launched their international business in 1999. They specialize in painting, calligraphy, and ceramics from the Momoyama up to the Taisho Period, 16th to early 20th centuries. Dealing always was and still is their main business. Nevertheless consulting and curating have become more and more important, for both private clients, and museums. Whereas consulting can be a short term assignment in the process of decision shaping and decision making, curating tends to be a long term involvement with a collection. Depending on the client’s vision, we can help the client to create strategies to build, to improve, or to dissolve a collection. BachmannEckenstein | JapaneseArt are based in Basel the cultural capital of Switzerland, right in the center of the old continent and half way between Japan and the United States. They are regular participants and exhibitors of New York Asia Week. Exhibitions in their gallery in a 19th century residential building are held occasionally.